What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His scientific interests lie mostly in Internal medicine, Oncology, Renal cell carcinoma, Carcinoma and Surgery.
His Internal medicine research focuses on Pathology and how it connects with PD-L1.
He combines subjects such as Survival rate, Clinical trial, Randomized controlled trial and Hazard ratio with his study of Oncology.
His study looks at the relationship between Renal cell carcinoma and fields such as Clinical endpoint, as well as how they intersect with chemical problems.
His Carcinoma research is multidisciplinary, incorporating perspectives in Phases of clinical research, Retrospective cohort study, Combined Modality Therapy, Tyrosine-kinase inhibitor and Biomarker.
His Surgery research focuses on subjects like Urology, which are linked to Nivolumab.
His most cited work include:
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma (3172 citations)
- Comprehensivemolecular characterization of clear cell renal cell carcinoma (1909 citations)
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma (1476 citations)
What are the main themes of his work throughout his whole career to date?
Toni K. Choueiri mostly deals with Internal medicine, Oncology, Renal cell carcinoma, Cancer and Sunitinib.
His Internal medicine study frequently draws connections to other fields, such as Surgery.
Toni K. Choueiri studied Surgery and Urology that intersect with Nephrectomy.
His Oncology research incorporates themes from Nivolumab, Randomized controlled trial, Proportional hazards model and Chemotherapy.
His research integrates issues of Targeted therapy, Carcinoma and Cancer research in his study of Renal cell carcinoma.
The concepts of his Sunitinib study are interwoven with issues in Bevacizumab, Temsirolimus and Kidney cancer.
He most often published in these fields:
- Internal medicine (67.44%)
- Oncology (55.49%)
- Renal cell carcinoma (48.09%)
What were the highlights of his more recent work (between 2019-2021)?
- Renal cell carcinoma (48.09%)
- Internal medicine (67.44%)
- Oncology (55.49%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Renal cell carcinoma, Internal medicine, Oncology, Cancer research and Cancer.
His Renal cell carcinoma study deals with Hazard ratio intersecting with Urology.
While working on this project, he studies both Internal medicine and In patient.
His Oncology study integrates concerns from other disciplines, such as Pembrolizumab, Immunotherapy, Targeted therapy and First line.
His Cancer research research includes elements of Immune checkpoint, Phenotype, Clear cell renal cell carcinoma, DNA and Carcinoma.
His Cancer research integrates issues from Cohort study and MEDLINE.
Between 2019 and 2021, his most popular works were:
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. (468 citations)
- Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer (56 citations)
- Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma (48 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Toni K. Choueiri mainly investigates Internal medicine, Renal cell carcinoma, Oncology, Cancer and Sunitinib.
In his articles, Toni K. Choueiri combines various disciplines, including Internal medicine and In patient.
His Renal cell carcinoma study incorporates themes from Cancer research, Adverse effect, Hazard ratio, Confidence interval and Carcinoma.
His Carcinoma research includes themes of Metastatic Urothelial Carcinoma, PD-L1 and Hypoxia.
His work carried out in the field of Oncology brings together such families of science as Biomarker and Blockade.
His biological study spans a wide range of topics, including Observational study, Cohort study and MEDLINE.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
